ipo
Stage
2
Investors
About
Science Seralutinib Seralutinib is an inhaled PDGFRα/β, CSF1R, and c‑KIT inhibitor designed to be delivered via dry powder inhaler for the potential treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Explore Gossamer Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.